Stock Analiz

DNA X, Inc. SONM

Telecommunications Equipment · IPO 2019 · data as of November 13, 2026

$2.17Market cap $3M
Open the interactive analysis →

DNA X, Inc. (SONM) is a utility company listed in the US with a market value of about $3M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -71%.

About DNA X

DNA X is listed in the US and classified in telecommunications equipment, IPO year 2019. Revenue went from $136M in 2018 to $58M in 2024, a decline of about 13.1% a year. It was profitable in 1 of the last 8 years in our data. Its share count rose by 338% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-37.2%
ROIC (5-yr avg.)-70.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue—$58M$94M$70M$55M$64M$116M$136M
Net income-$21M-$34M-$90000-$14M-$39M-$30M-$26M$1M
Free cash flow—-$9M-$4M-$12M-$39M-$11M-$35M$3M
EPS (diluted)$-28.58$-128.37$-0.36$-85.76$-714.06$-1134.10$-2432.73$-4497.92
Net margin—-57.7%-0.1%-20.2%-70.8%-46.8%-22.2%0.9%
ROIC——1.8%-55.7%-158.8%-100.0%-49.5%18.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does DNA X pay a dividend?

Not currently.

Is DNA X a good stock to buy?

We do not give buy or sell advice. DNA X scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.